A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

Clinical trial NCT03655678 · COMPLETED

Trial details

NCT number: NCT03655678
Sponsor: Vertex Pharmaceuticals Incorporated
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Beta-Thalassemia Thalassemia Genetic Diseases, Inborn Hematologic Diseases Hemoglobinopathies

Start date: 2018-09-14
Primary completion: 2025-11-13
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.